Bachem Holding AG Class B · SIX:BANB
Bachem Holding AG Class B — FY2020 Earnings Presentation
27 slides from Bachem Holding AG Class B's earnings presentation, Mar 12, 2021
Slide 1: Bachem Full Year Results 2020
BACHEM FULL YEAR RESULTS 2020 Date | March 12, 2021 Location | Bubendorf Name | Thomas Meier / Alain Schaffter
Slide 2: Speakers
SPEAKERS Thomas Meier Alain Schaffter CEO CFO 2 Full-Year Results 2020
Slide 3: Housekeeping
HOUSEKEEPING Write to us in the Q&A section anytime. At the end of the presentation we will have time for questions. 3 Full Year Results 2020
Slide 4: Agenda
AGENDA • Welcome and Introduction Thomas Meier • Results and Business Review 2020 Thomas Meier • Financial Review 2020 Alain Schaffter • Outlook 2021 Thomas Meier • Q&A All 4 Full Year Results 2020
Slide 5: Results and Business Review 2020
RESULTS AND BUSINESS REVIEW 2020 Thomas Meier
Slide 6: Bachem Reports Excellent Results in 2020
BACHEM REPORTS EXCELLENT RESULTS IN 2020 Strong Revenue Growth Significantly Improved Profitability • 1st time > 400 million CHF • EBITDA 122.6 million CHF (+40.5%) • 28.1% sales growth (34.0% in local currencies) • EBITDA margin 30.5% (2019: 27.8%) • Growth in all product categories and • EBIT 96.7
Slide 7: Key Figures 2020
KEY FIGURES 2020 2020 2019 Change CHF Change LC Sales (in MCHF) 402.0 313.7 + 28.1% + 34.0% EBITDA (in MCHF) 122.6 87.2 + 40.5% + 55.3% in relation to sales 30.5% 27.8% EBIT (in MCHF) 96.7 62.4 + 55.0% + 75.3% in relation to sales 24.0% 19.9% Net income (in MCHF) 78.1 54.2 + 44.1% in relation to sal
Slide 8: Growth in All Product Categories
GROWTH IN ALL PRODUCT CATEGORIES Change in in million CHF 2020 Change in CHF Sales share local currency Active Pharmaceutical Ingredients (APIs) 360.4 + 36.4% + 30.3% 89.6% Research Chemicals 41.6 + 16.5% + 12.2% 10.4% Total sales 402.0 + 34.0% + 28.1% 100.0% Excellent growth in all product categori
Slide 9: Geographically Balanced
GEOGRAPHICALLY BALANCED Change in in million CHF 2020 Change in CHF Sales share local currency Europe/Asia 185.0 + 19.4% + 16.7% 46.0% North America 217.0 + 48.9% + 39.9% 54.0% Total sales 402.0 + 34.0% + 28.1% 100.0% All regions contributed to the growth: Europe increased by 15%. Asia increased by
Slide 10: Well Balanced Customer & Product Mix
WELL BALANCED CUSTOMER & PRODUCT MIX IN % OF SALES Customers Products 80.0 80.0 60.0 60.0 40.0 40.0 20.0 20.0 0.0 0.0 2018 2019 2020 2018 2019 2020 Top 20 Top 10 Top 5 10 Full-Year Results 2020
Slide 11: COVID-19: Overall No Significant Impact on Result
COVID-19: OVERALL NO SIGNIFICANT IMPACT ON RESULT Operations Positive Effects Negative Effects • Business Contingency Plan in place • The systemic relevance of our • Delayed clinical trials from day 1 business as a manufacturer of active • Delayed drug approvals • Successful protection concept for p
Slide 12: Worldwide Presence / 1529 Employees
WORLDWIDE PRESENCE / 1529 EMPLOYEES TORRANCE (CA) BUBENDORF (CH) Acquired in 1996 Founded in 1971 269 employees 964 employees VISTA (CA) TOKYO (JP) Acquired in 2015 Established in 2018 132 employees 4 employees ST.HELENS (UK) VIONNAZ (CH) Acquired in 1999 Acquired in 2001 44 employees 116 employees
Slide 13: Leading Partner in TIDES
• Our business is peptides and now also oligonucleotides. LEADING • Oligonucleotides and peptides are PARTNER complex biomolecules that open IN TIDES up so far undruggable therapeutic targets. 13 Full-Year Results 2020
Slide 14: Financial Review 2020
FINANCIAL REVIEW 2020 Alain Schaffter
Slide 15: Key Figures 2020
KEY FIGURES 2020 2020 2019 Change CHF Change LC Sales (in MCHF) 402.0 313.7 + 28.1% + 34.0% EBITDA (in MCHF) 122.6 87.2 + 40.5% + 55.3% in relation to sales 30.5% 27.8% EBIT (in MCHF) 96.7 62.4 + 55.0% + 75.3% in relation to sales 24.0% 19.9% Net income (in MCHF) 78.1 54.2 + 44.1% in relation to sal
Slide 16: Drivers of EBIT Margin Increase from 19.9% to 24.0%
DRIVERS OF EBIT MARGIN INCREASE FROM 19.9% TO 24.0% IN % +2097bps 0.6 24.0 1.1 -0.2 2.6 19.9 EBIT 2019 COGS M&S R&D G&A /other income EBIT 2020 16 Full-Year Results 2020
Slide 17: Increased Operating Cash Flow by 79% to 115 Million CHF
INCREASED OPERATING CASH FLOW BY 79% TO 115 MILLION CHF IN MCHF +79% -2.0 115.0 117.0 115.0 2.6 -30.1 25.5 -69.3 64.3 -43.1 -0.6 2.1 Operating Cash Operating Cash Operating Change in Change in Change in Operating Investing Financing Currency Net Flow 2019 Flow 2020 CF before receivables inventory pa
Slide 18: Stable Equity Ratio
STABLE EQUITY RATIO IN MCHF 106.8 107.3 25.0 647.1 710.9 46.8 22.3 199.3 235.2 (31%) (33%) 447.8 475.7 (69%) (67%) 60.0 60.0 Liabilities Equity 31.12.2019 31.12.2020 31.12.2019 31.12.2020 Current loan Ingro Finanz AG Current loans bank Non-current loans bank 18 Full-Year Results 2020
Slide 19: Capex Overview 2016-2020
CAPEX OVERVIEW 2016-2020 76.4 51.3 50.4 38.6 32.7 24.9 25.9 23.1 21.7 20.9 19.7 19.3 19.0 13.7 10.4 2016 2017 2018 2019 2020 CAPEX in MCHF Depreciation in MCHF CAPEX in % of sales 19 Full-Year Results 2020
Slide 20: Outlook 2021
OUTLOOK 2021 Thomas Meier BACHEM LEADING PARTNER IN TIDES
Slide 21: Outlook 2021 – Celebrating the First 50 Years
OUTLOOK 2021 – CELEBRATING THE FIRST 50 YEARS Bachem celebrates fifty years of company history. From Peter Grogg's business idea in the 1970s to the world's leading company in the development and production of peptides and oligonucleotides. A success story based on courage, innovation, quality, part
Slide 22: Dynamics & Growth Drivers
Internal factors • NCE pipeline with 150 projects • Focused oligonucleotide product extension • Increasing demand of synthetic vs. recombinant manufacturing • Capacity investments in all GMP locations for future growth DYNAMICS & GROWTH DRIVERS External factors • Aging population • Outsourcing trend
Slide 23: Outlook 2021: Commitment to Profitable Growth
OUTLOOK 2021: COMMITMENT TO PROFITABLE GROWTH • Sales: Above 500 million CHF in 2022. • Profit: A percentage growth above that of sales. • Capacity: Global investment volume of over 400 million CHF in the next 5 years. 23 Full Year Results 2020
Slide 24: Questions
QUESTIONS Write your questions in the Q&A section
Slide 25: Thank You for Your Attendance!
THANK YOU FOR YOUR ATTENDANCE! Question? Send an e-mail to… [email protected] 25 Full Year Results 2020
Slide 26: Disclaimer
DISCLAIMER This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other
Slide 27: Leading Partner in TIDES
LEADING PARTNER IN TID BACHEM 4